How deadly is Colon cancer?

Lalela leli khasi

Umdlavuza wamathumbu uyabulala kangakanani?

Umdlavuza wamathumbu, owaziwa nangokuthi umdlavuza wamathumbu, uyisifo esibucayi futhi esingabulala.

Ungumdlavuza wesithathu ovame kakhulu e-United States futhi uyimbangela yesibili yokufa ngenxa yomdlavuza.

Izinga eliphelele lokuphila iminyaka emihlanu ngomdlavuza wamathumbu cishe liyi-65%, kodwa lokhu kuyahlukahluka kuye ngesigaba lapho umdlavuza utholakala khona.

Uma kutholakala kusenesikhathi, izinga lokusinda eminyakeni emihlanu lingaba ngama-90%, kodwa uma umdlavuza ususakazekele kwezinye izingxenye zomzimba, izinga lokusinda lehla libe cishe ngama-111%. Ukutholakala nokwelashwa kusenesikhathi kubalulekile ekuthuthukiseni amathuba okusinda.

Kubalulekile ukuphawula ukuthi amazinga okusinda ayizilinganiso kuphela futhi imiphumela yomuntu ngamunye ingahluka.

Ukuhlolwa njalo nokwelashwa ngokushesha kunganciphisa ngokuphawulekayo ingozi yokuthi umdlavuza wamathumbu ungabulala.

Izikhombo

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Andersen LD, Remington P, Trentham-Dietz A, Reeves M: Assessing a decade of progress in cancer control. Oncologist. 2002, 7 (3): 200-4.

Wang YG, Chen KX, Wu GL, Song FJ: An analysis: colon cancer mortality in Tianjin, China, from 1981 to 2000. World J Gastroenterol. 2005, 11 (6): 895-8.

Tsuji K, Harashima E, Nakagawa Y, Urata G, Shirataka M: Time-lag effect of dietary fiber and fat intake ratio on Japanese colon cancer mortality. Biomed Environ Sci. 1996, 9 (2-3): 223-8.

Kanter MH, Schottinger JE, Joshua A, Slezak JM: Beyond Screening: An Interim Report and Analysis of a Multimodal Initiative to Decrease Colon Cancer Mortality. Jt Comm J Qual Patient Saf. 2022, 48 (8): 388-394.

Tseng CH: Diabetes but not insulin is associated with higher colon cancer mortality. World J Gastroenterol. 2012, 18 (31): 4182-90.

Jacobs EJ, Connell CJ, Patel AV, Chao A, Rodriguez C, Seymour J, McCullough ML, Calle EE, Thun MJ: Multivitamin use and colon cancer mortality in the Cancer Prevention Study II cohort (United States). Cancer Causes Control. 2001, 12 (10): 927-34.

Ukuzikhulula: kwezokwelapha

Le webhusayithi inikezwa ngezinjongo zemfundo nezokwaziswa kuphela futhi ayifaki ukunikeza izeluleko zezokwelapha noma izinsizakalo zobungcweti.

Imininingwane enikeziwe akufanele isetshenziselwe ukuxilonga noma ukwelapha inkinga noma isifo, futhi labo abafuna iseluleko somuntu siqu sezokwelapha kufanele babonane nodokotela onelayisense.

Sicela uqaphele ukuthi inethiwekhi ye-neural ekhiqiza izimpendulo zemibuzo, ayinembile ngokukhethekile uma kuziwa kokuqukethwe kwezinombolo. Ngokwesibonelo, inani labantu abanesifo esithile.

Ngaso sonke isikhathi funa iseluleko sikadokotela wakho noma omunye umhlinzeki wezempilo ofanelekayo mayelana nesimo sezokwelapha. Ungalokothi ungayinaki iseluleko sezokwelapha sobungcweti noma ubambezele ukusifuna ngenxa yento oyifundile kule webhusayithi. Uma ucabanga ukuthi ungase ube nesimo esiphuthumayo sezokwelapha, shayela i-911 noma uye egumbini lezimo eziphuthumayo eliseduze ngokushesha. Ayikho ubudlelwano bokuthi udokotela-isiguli obakhiwe yile webhusayithi noma ukusetshenziswa kwayo. I-BioMedLib noma abasebenzi bayo, noma noma yimuphi umnikeli wale webhusayithi, akenzi noma yimiphi imibono, ecacile noma ecacile, mayelana nolwazi olunikezwe lapha noma ukusetshenziswa kwayo.

Ukuzikhulula: amalungelo obunikazi

I-Digital Millennium Copyright Act ka-1998, i-17 U.S.C. § 512 (i- DMCA) inikeza indlela yokuphendula kubanikazi bamalungelo obunikazi abakholelwa ukuthi okokusebenza okubonakala kwi-Internet kwephula amalungelo abo ngaphansi komthetho we-copyright wase-US.

Uma ukholelwa ngobuqotho ukuthi noma yikuphi okuqukethwe noma okokusebenza okwenziwe kutholakale maqondana newebhusayithi yethu noma izinsizakalo kwephula ilungelo lakho lobunikazi, wena (noma umenzeli wakho) ungasithumela isaziso esicela ukuthi okuqukethwe noma okokusebenza kususwe, noma ukufinyelela kukho kuvinjelwe.

Izaziso kufanele zithunyelwe ngokubhala nge-imeyili (bheka isigaba esithi "Contact" ukuze uthole ikheli le-imeyili).

I-DMCA idinga ukuthi isaziso sakho sokwephulwa kwamalungelo obunikazi kubandakanye imininingwane elandelayo: (1) incazelo yomsebenzi onamalungelo obunikazi oyisihloko sokwephulwa okusolwa; (2) incazelo yokuqukethwe okusolwa ukwephula amalungelo obunikazi nolwazi olwanele ukusivumela ukuthi sithole okuqukethwe; (3) imininingwane yokuxhumana nawe, kufaka phakathi ikheli lakho, inombolo yocingo nekheli le-imeyili; (4) isitatimende sakho sokuthi unokholo oluhle lokuthi okuqukethwe ngendlela ekhonjiwe ngayo akugunyaziwe ngumnikazi wamalungelo obunikazi, noma umenzeli wakhe, noma ngokusebenza kwanoma imuphi umthetho;

(5) isitatimende sakho, esisayinwe ngaphansi kwesijeziso sokufakaza amanga, sokuthi ukwaziswa okusesazisweni kunembile nokuthi unegunya lokuphoqelela amalungelo obunikazi okuthiwa aphuliwe;

futhi (6) isignesha ebonakalayo noma ye-elekthronikhi yomnikazi we-copyright noma umuntu ogunyaziwe ukuba asebenze egameni lomnikazi we-copyright.

Ukwehluleka ukufaka yonke imininingwane engenhla kungaholela ekubambezelweni kokucutshungulwa kwesikhalazo sakho.

Othintana naye

Sicela usithumelele i-imeyili nganoma yimiphi imibuzo / iziphakamiso.

How deadly is colon cancer?

Colon cancer, also known as colorectal cancer, is a serious and potentially deadly disease.

It is the third most common cancer in the United States and the second leading cause of cancer deaths.

The overall 5-year survival rate for colon cancer is approximately 65%, but this varies depending on the stage at which the cancer is diagnosed.

If caught early, the 5-year survival rate can be as high as 90%, but if the cancer has spread to other parts of the body, the survival rate drops to around 111%. Early detection and treatment are crucial for improving the chances of survival.

It is important to note that survival rates are only estimates and individual outcomes may vary.

Regular screening and prompt treatment can significantly reduce the risk of colon cancer becoming deadly.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.